Message Font: Serif | Sans-Serif
No. of Recommendations: 1
Here is the list so far. JPG, I cant find renovo on google finance or on ... can you pick another?

Fuma102- SQNM & OSIP
Joseph- VICL & CVM
vision2010- ELN & VVUS
projectchris- NEOP.ob & SPPI
Helical- HLCS & CALP

Also, any choices from shuksan? sarah? missash? CSOakes? Wadigo? Gillett? Applefoot? beautifulplumage? DavidMN? DartthrowingMonkey?

The OSIP pitch: PE of 5, market cap of 1.8b, EPS of 6.3, tarceva got labeled for lung cancer maintenance so it might get prescribed more, they just have nothing worthwhile in the pipeline. Still the least risky more rewarding biotech I see. Other thoughts I had:

BDSI for its oral amphotericin
shorting ALNY & its RNAi, shorting INCY
CBST for dapto & its new acquisition
XOMA for XOMA052, a longshot diabetes drug
OSIR for Prochymal, which looks somewhat promising in graft rejections

I own SQNM, but will pick up CBST if it drops significantly from today's $20 mark.
Print the post  


When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.